Challenges of modifying disease progression in prediagnostic Parkinson's disease

The Lancet Neurology

Volumn 15, Issue 6, 2016, Pages 637-648

  Salat, David ^a   Noyce, Alastair J ^b   Schrag, Anette ^c   Tolosa, Eduardo ^d  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; BIOLOGICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT; CREATINE; DEFERIPRONE; EXENDIN 4; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTATHIONE; NONSTEROID ANTIINFLAMMATORY AGENT; PRAMIPEXOLE; RASAGILINE; SELEGILINE; TOCOPHEROL; UBIDECARENONE; URSODEOXYCHOLIC ACID;

AUTOSOMAL DOMINANT INHERITANCE; DISEASE COURSE; ETHICS; EXCITOTOXICITY; GENE MUTATION; HUMAN; HYPOSMIA; LEWY BODY; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROIMAGING; OUTCOME ASSESSMENT; PARASOMNIA; PARKINSON DISEASE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; PRODROMAL SYMPTOM;

BIOMARKERS; DISEASE PROGRESSION; HUMANS; PARKINSON DISEASE; PRODROMAL SYMPTOMS;

EID: 84961193036     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(16)00060-0     Document Type: Review

References (98)

1. Fearnley JM, Lees AJ Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991, 114:2283-2301.
2. Irwin DJ, Lee VM, Trojanowski JQ Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies. Nat Rev Neurosci 2013, 14:626-636.
3. Tolosa E, Marti MJ, Katzenschlager K Pharmacological management of Parkinson's disease. Parkinson's Disease & Movement Disorders 2015, 86-111. Wolters Kluwer, Philadelphia, PA. 6th edn. J. Jancovic, E. Tolosa (Eds.).
4. Poewe W, Mahlknecht P The clinical progression of Parkinson's disease. Parkinsonism Relat Disord 2009, 15(suppl 4):S28-S32.
5. Hely MA, Morris JG, Reid WG, Trafficante R Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005, 20:190-199.
6. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989, 321:1364-1371. The Parkinson Study Group.
7. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 2007, 68:20-28. NINDS NET-PD Investigators.
8. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009, 361:1268-1278. for the ADAGIO Study Investigators.
9. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003, 24:197-211.
10. Dexter DT, Jenner P Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med 2013, 62:132-144.
11. Blesa J, Phani S, Jackson-Lewis V, Przedborski S Classic and new animal models of Parkinson's disease. J Biomed Biotechnol 2012, 2012:845618.
12. Ryan BJ, Hoek S, Fon EA, Wade-Martins R Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease. Trends Biochem Sci 2015, 40:200-210.
13. Celardo I, Martins LM, Gandhi S Unravelling mitochondrial pathways to Parkinson's disease. Br J Pharmacol 2014, 171:1943-1957.
14. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 1990, 54:823-827.
15. Simcox EM, Reeve A, Turnbull D Monitoring mitochondrial dynamics and complex I dysfunction in neurons: implications for Parkinson's disease. Biochem Soc Trans 2013, 41:1618-1624.
16. Schapira AH, Tolosa E Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat Rev Neurol 2010, 6:309-317.
17. Savica R, Carlin JM, Grossardt BR, et al. Medical records documentation of constipation preceding Parkinson disease: a case-control study. Neurology 2009, 73:1752-1758.
18. Fang F, Xu Q, Park Y, et al. Depression and the subsequent risk of Parkinson's disease in the NIH-AARP Diet and Health Study. Mov Disord 2010, 25:1157-1162.
19. Ross GW, Petrovitch H, Abbott RD, et al. Association of olfactory dysfunction with risk for future Parkinson's disease. Ann Neurol 2008, 63:167-173.
20. Ross GW, Abbott RD, Petrovitch H, Tanner CM, White LR Pre-motor features of Parkinson's disease: the Honolulu-Asia Aging Study experience. Parkinsonism Relat Disord 2012, 18(suppl 1):S199-S202.
21. Schrag A, Horsfall L, Walters K, Noyce A, Petersen I Prediagnostic presentations of Parkinson's disease in primary care: a case-control study. Lancet Neurol 2015, 14:57-64.
22. Noyce AJ, Bestwick JP, Silveira-Moriyama L, et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol 2012, 72:893-901.
23. Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters EC, Berendse HW Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 2004, 56:173-181.
24. Iranzo A, Fernández-Arcos A, Tolosa E, et al. Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients. PLoS One 2014, 9:e89741.
25. Postuma RB, Lang AE, Gagnon JF, Pelletier A, Montplaisir JY How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder. Brain 2012, 135:1860-1870.
26. Tolosa E, Gaig C, Santamaría J, Compta Y Diagnosis and the premotor phase of Parkinson disease. Neurology 2009, 72(suppl):S12-S20.
27. Wu Y, Le W, Jankovic J Preclinical biomarkers of Parkinson disease. Arch Neurol 2011, 68:22-30.
28. Iranzo A, Molinuevo JL, Santamaría J, et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol 2006, 5:572-577.
29. Sommer U, Hummel T, Cormann K, et al. Detection of presymptomatic Parkinson's disease: combining smell tests, transcranial sonography, and SPECT. Mov Disord 2004, 19:1196-1202.
30. Mirelman A, Gurevich T, Giladi N, Bar-Shira A, Orr-Urtreger A, Hausdorff JM Gait alterations in healthy carriers of the LRRK2 G2019S mutation. Ann Neurol 2011, 69:193-197.
31. San Luciano M, Lipton RB, Wang C, et al. Clinical expression of LRRK2 G2019S mutations in the elderly. Mov Disord 2010, 25:2571-2576.
32. Beavan M, McNeill A, Proukakis C, Hughes DA, Mehta A, Schapira AH Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort. JAMA Neurol 2015, 72:201-208.
33. Hawkes C Olfaction in neurodegenerative disorder. Mov Disord 2003, 18:364-372.
34. Fernández-Santiago R, Iranzo A, Gaig C, et al. MicroRNA association with synucleinopathy conversion in rapid eye movement behavior disorder. Ann Neurol 2015, 77:895-901.
35. Marras C, Schüle B, Munhoz RP, et al. Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers. Neurology 2011, 77:325-333.
36. Nandhagopal R, Mak E, Schulzer M, et al. Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study. Neurology 2008, 71:1790-1795.
37. Schenck CH, Bundlie SR, Mahowald MW Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 1996, 46:388-393.
38. Fereshtehnejad SM, Romenets SR, Anang JB, Latreille V, Gagnon JF, Postuma RB New clinical subtypes of Parkinson disease and their longitudinal progression: a prospective cohort comparison with other phenotypes. JAMA Neurol 2015, 72:863-873.
39. Berg D, Godau J, Seppi K, et al. The PRIPS study: screening battery for subjects at risk for Parkinson's disease. Eur J Neurol 2013, 20:102-108. for the PRIPS study group.
40. Jennings D, Siderowf A, Stern M, et al. Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study. Neurology 2014, 83:1739-1746. for the PARS Investigators.
41. Siderowf A, Jennings D, Eberly S, et al. Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome Study. Mov Disord 2012, 27:406-412. for the PARS Investigators.
42. Gaenslen A, Wurster I, Brockmann K, et al. Prodromal features for Parkinson's disease-baseline data from the TREND study. Eur J Neurol 2014, 21:766-772.
43. Lerche S, Brockmann K, Wurster I, et al. Reasons for mild parkinsonian signs-which constellation may indicate neurodegeneration?. Parkinsonism Relat Disord 2015, 21:126-130.
44. Noyce AJ, Bestwick JP, Silveira-Moriyama L, et al. PREDICT-PD: identifying risk of Parkinson's disease in the community: methods and baseline results. J Neurol Neurosurg Psychiatry 2014, 85:31-37.
45. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol 2011, 95:629-635. Parkinson Progression Marker Initiative.
46. Berg D, Postuma RB, Adler CH, et al. MDS research criteria for prodromal Parkinson's disease. Mov Disord 2015, 30:1600-1611.
47. Schneider SA, Boettner M, Alexoudi A, et al. Can we use peripheral tissue biopsies to diagnose Parkinson's disease? A review of the literature. Eur J Neurol 2015, 23:247-261.
48. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993, 328:176-183. Parkinson Study Group.
49. Schapira AH, McDermott MP, Barone P, et al. Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. Lancet Neurol 2013, 12:747-755.
50. Aviles-Olmos I, Dickson J, Kefalopoulou Z, et al. Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease. J Parkinsons Dis 2014, 4:337-344.
51. Knight A Animal experiments scrutinised: systematic reviews demonstrate poor human clinical and toxicological utility. ALTEX 2007, 24:320-325.
52. Busche MA, Grienberger C, Keskin AD, et al. Decreased amyloid-β and increased neuronal hyperactivity by immunotherapy in Alzheimer's models. Nat Neurosci 2015, 18:1725-1727.
53. Johnson CD, Davidson BL Huntington's disease: progress toward effective disease-modifying treatments and a cure. Hum Mol Genet 2010, 19:R98-102.
54. Galimberti D, Scarpini E Disease-modifying treatments for Alzheimer's disease. Ther Adv Neurol Disord 2011, 4:203-216.
55. Siciliano G, Carlesi C, Pasquali L, et al. Clinical trials for neuroprotection in ALS. CNS Neurol Disord Drug Targets 2010, 9:305-313.
56. Hughes AJ, Daniel SE, Kilford L, Lees AJ Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992, 55:181-184.
57. Buchman AS, Shulman JM, Nag S, et al. Nigral pathology and parkinsonian signs in elders without Parkinson disease. Ann Neurol 2012, 71:258-266.
58. Johansen KK, White LR, Farrer MJ, Aasly JO Subclinical signs in LRRK2 mutation carriers. Parkinsonism Relat Disord 2011, 17:528-532.
59. Tabrizi SJ, Reilmann R, Roos RA, et al. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol 2012, 11:42-53.
60. Marek K, Jennings D Can we image premotor Parkinson disease?. Neurology 2009, 72(suppl):S21-S26.
61. Hilker R, Schweitzer K, Coburger S, et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol 2005, 62:378-382.
62. Scherfler C, Schwarz J, Antonini A, et al. Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov Disord 2007, 22:1229-1238.
63. Iranzo A, Valldeoriola F, Lomeña F, et al. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol 2011, 10:797-805.
64. Winogrodzka A, Bergmans P, Booij J, van Royen EA, Janssen AG, Wolters EC [123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease. J Neural Transm (Vienna) 2001, 108:1011-1019.
65. Pirker W, Djamshidian S, Asenbaum S, et al. Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study. Mov Disord 2002, 17:45-53.
66. Seibyl JP, Marek K, Sheff K, et al. Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients. J Nucl Med 1997, 38:1453-1459.
67. Pavese N, Brooks DJ Imaging neurodegeneration in Parkinson's disease. Biochim Biophys Acta 2009, 1792:722-729.
68. Pyatigorskaya N, Gallea C, Garcia-Lorenzo D, Vidailhet M, Lehericy S A review of the use of magnetic resonance imaging in Parkinson's disease. Ther Adv Neurol Disord 2014, 7:206-220.
69. Brockmann K, Gröger A, Di Santo A, et al. Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers. Mov Disord 2011, 26:2335-2342.
70. Scherfler C, Frauscher B, Schocke M, et al. White and gray matter abnormalities in idiopathic rapid eye movement sleep behavior disorder: a diffusion-tensor imaging and voxel-based morphometry study. Ann Neurol 2011, 69:400-407. for the SINBAR (Sleep Innsbruck Barcelona) Group.
71. Sharma S, Moon CS, Khogali A, et al. Biomarkers in Parkinson's disease (recent update). Neurochem Int 2013, 63:201-229.
72. Foulds PG, Diggle P, Mitchell JD, et al. A longitudinal study on α-synuclein in blood plasma as a biomarker for Parkinson's disease. Sci Rep 2013, 3:2540.
73. Berg D, Behnke S, Seppi K, et al. Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease. Mov Disord 2013, 28:216-219.
74. Iranzo A, Lomeña F, Stockner H, et al. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol 2010, 9:1070-1077. for the Sleep Innsbruck Barcelona (SINBAR) group.
75. Postuma RB, Gagnon JF, Bertrand JA, Génier Marchand D, Montplaisir JY Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials. Neurology 2015, 84:1104-1113.
76. Sierra M, Sánchez-Juan P, Martínez-Rodríguez MI, et al. Olfaction and imaging biomarkers in premotor LRRK2 G2019S-associated Parkinson disease. Neurology 2013, 80:621-626.
77. Vilas D, Ispierto L, Álvarez R, et al. Clinical and imaging markers in premotor LRRK2 G2019S mutation carriers. Parkinsonism Relat Disord 2015, 21:1170-1176.
78. Huleatt PB, Khoo ML, Chua YY, et al. Novel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's disease. J Med Chem 2015, 58:1400-1419.
79. Wang S, Jing H, Yang H, et al. Tanshinone I selectively suppresses pro-inflammatory genes expression in activated microglia and prevents nigrostriatal dopaminergic neurodegeneration in a mouse model of Parkinson's disease. J Ethnopharmacol 2015, 164:247-255.
80. Zhang Z, Li G, Szeto SS, et al. Examining the neuroprotective effects of protocatechuic acid and chrysin on in vitro and in vivo models of Parkinson disease. Free Radic Biol Med 2015, 84:331-343.
81. Spencer B, Emadi S, Desplats P, et al. ESCRT-mediated uptake and degradation of brain-targeted α-synuclein single chain antibody attenuates neuronal degeneration in vivo. Mol Ther 2014, 22:1753-1767.
82. Tran HT, Chung CH, Iba M, et al. A-synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration. Cell Reports 2014, 7:2054-2065.
83. Patel NK, Bunnage M, Plaha P, Svendsen CN, Heywood P, Gill SS Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann Neurol 2005, 57:298-302.
84. Marks WJ, Ostrem JL, Verhagen L, et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol 2008, 7:400-408.
85. Marks WJ, Bartus RT, Siffert J, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2010, 9:1164-1172.
86. Mortiboys H, Aasly J, Bandmann O Ursocholanic acid rescues mitochondrial function in common forms of familial Parkinson's disease. Brain 2013, 136:3038-3050.
87. Alcalay RN, Gu Y, Mejia-Santana H, Cote L, Marder KS, Scarmeas N The association between Mediterranean diet adherence and Parkinson's disease. Mov Disord 2012, 27:771-774.
88. Chao J, Leung Y, Wang M, Chang RC Nutraceuticals and their preventive or potential therapeutic value in Parkinson's disease. Nutr Rev 2012, 70:373-386.
89. Duncan RP, Earhart GM Are the effects of community-based dance on Parkinson disease severity, balance, and functional mobility reduced with time? A 2-year prospective pilot study. J Altern Complement Med 2014, 20:757-763.
90. Shu HF, Yang T, Yu SX, et al. Aerobic exercise for Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials. PLoS One 2014, 9:e100503.
91. Frazzitta G, Maestri R, Bertotti G, et al. Intensive rehabilitation treatment in early Parkinson's disease: a randomized pilot study with a 2-year follow-up. Neurorehabil Neural Repair 2015, 29:123-131.
92. Fisher BE, Li Q, Nacca A, et al. Treadmill exercise elevates striatal dopamine D2 receptor binding potential in patients with early Parkinson's disease. Neuroreport 2013, 24:509-514.
93. Park A, Zid D, Russell J, et al. Effects of a formal exercise program on Parkinson's disease: a pilot study using a delayed start design. Parkinsonism Relat Disord 2014, 20:106-111.
94. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013, 310:2191-2194. World Medical Association.
95. Rosas HD, Doros G, Gevorkian S, et al. PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease. Neurology 2014, 82:850-857.
96. Moulder KL, Snider BJ, Mills SL, et al. Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. Alzheimers Res Ther 2013, 5:48.
97. Corti O, Fournier M, Brice A Neurodegeneration in Parkinson's disease: genetics enlightens physiopathology. J Neural Transm Suppl 2009, 73:215-221.
98. Lang AE Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future. Nat Med 2010, 16:1223-1226.